| abstract |
Disclosed is an oncolytic therapeutic agent for cancer having improved in vivo ability of gene transfer and / or lysis destruction of tumor cells. The present invention includes a herpes simplex virus 1 (HSV1), wherein the HSV1 is a gene having the following (i) to (ii), the gene is under the control of a promoter, and the promoter is a ubiquitous promoter or A therapeutic agent that is a viral promoter. The therapeutic agent whose said immunostimulatory protein is cytokine or human GM-CSF. (i) lacks a functional ICP34.5 coding gene; (ii) lacks a functional ICP47 coding gene; and (iii) contains a gene encoding an immunostimulatory protein [selection figure] None |